

Regulatory Affairs

**SIMULECT®**

(Basiliximab)

20mg Powder and solvent for solution for infusion or injection.

**Summary of Product Characteristics (SmPC)**

**Version 3.1**

## Table of contents

Table of contents .....	2
1 Tradename .....	3
2 Description and composition .....	3
3 Indications .....	3
4 Dosage regimen and administration .....	4
5 Contraindications .....	4
6 Warnings and precautions .....	5
7 Adverse drug reactions .....	6
8 Interactions .....	7
9 Pregnancy, lactation, females and males of reproductive potential .....	8
9.1 Pregnancy .....	8
9.2 Lactation .....	8
9.3 Females and males of reproductive potential .....	8
10 Overdosage .....	9
11 Clinical pharmacology .....	9
12 Clinical studies .....	10
13 Non-clinical safety data .....	11
14 Pharmaceutical information .....	12
15 References .....	14
16 CDS history table .....	16

## 1 Tradename

SIMULECT®

## 2 Description and composition

One vial of Simulect® 10 mg contains 10 mg basiliximab [15].

One vial of Simulect® 20 mg contains 20 mg basiliximab.

An ampoule containing 5 mL water for injection is supplied for dissolution. Not all marketed presentations contain a water for injection ampoule.

### Pharmaceutical form(s)

Glass vials containing 10 mg sterile freeze-dried powder of basiliximab for intravenous infusion or injection after reconstitution with 2.5 mL water for injection.

Glass vials containing 20 mg sterile freeze-dried powder of basiliximab for intravenous infusion or injection after reconstitution with 5 mL water for injection.

### Active substance

Basiliximab

### Excipients

A vial of Simulect contains, in addition to basiliximab, potassium dihydrogen phosphate, disodium phosphate, anhydrous, sodium chloride, sucrose, mannitol, and glycine. A solvent ampoule contains water for injection. No preservatives are included. Not all marketed presentations contain a water for injection ampoule.

Information might differ in some countries.

## 3 Indications

Simulect is indicated for the prophylaxis of acute organ rejection in *de novo* renal transplantation in adult and pediatric [3] patients. It is to be used concomitantly with ciclosporin for microemulsion- and corticosteroid-based immunosuppression or in a triple maintenance immunosuppressive regimen containing ciclosporin for microemulsion, corticosteroids and either azathioprine [4] or mycophenolate mofetil [5,6].

## **4 Dosage regimen and administration**

### **Dosage regimen**

#### **General target population**

##### **Adults**

The standard total dose is 40 mg, given in two doses of 20 mg each. The first 20 mg dose should be given within 2 hours prior to transplantation surgery. Simulect must not be administered unless it is absolutely certain that the patient will receive the graft and concomitant immunosuppression [1]. The second 20 mg dose should be given 4 days after transplantation. The second dose should be withheld if severe hypersensitivity reactions to Simulect [1] or graft loss occur (see section 6 Warnings and precautions).

#### **Special populations:**

##### **Pediatric patients (below 18 years)**

In pediatric patients weighing less than 35 kg, the recommended total dose is 20 mg, given in two doses of 10 mg each [3,15]. In pediatric patients weighing 35 kg or more, the recommended dose is the adult dose, i.e. a total dose of 40 mg, given in two doses of 20 mg each [3]. The first dose should be given within 2 hours prior to transplantation surgery. Simulect must not be administered unless it is absolutely certain that the patient will receive the graft and concomitant immunosuppression [1]. The second dose should be given 4 days after transplantation. The second dose should be withheld if severe hypersensitivity reactions to Simulect [1] or graft loss occur (see section 6 Warnings and precautions).

##### **Geriatric patients (65 years or above)**

There are limited data available on the use of Simulect in the elderly, but there is no evidence that elderly patients require a different dosage from younger adult patients.

#### **Method of administration**

Reconstituted Simulect can be administered either as an intravenous infusion over 20-30 minutes or as a bolus injection.

For information on reconstituting Simulect, see section 14 Pharmaceutical information.

## **5 Contraindications**

Simulect is contraindicated in patients with known hypersensitivity to basiliximab or any other component of the formulation (see section 2 Description and composition).

## 6 Warnings and precautions

### General

Simulect should be prescribed only by physicians who are experienced in the use of immunosuppressive therapy following organ transplantation.

Patients receiving Simulect should be managed in facilities equipped and staffed with adequate laboratory and supportive medical resources including medications for the treatment of severe hypersensitivity reactions.

### Hypersensitivity reactions

Severe acute (less than 24 hours) hypersensitivity reactions have been observed both on initial exposure to Simulect and on reexposure to a subsequent course of therapy. These included anaphylactoid type reactions such as rash, urticaria, pruritus, sneezing, wheezing, hypotension, tachycardia, dyspnea, bronchospasm, pulmonary edema, cardiac failure respiratory failure and capillary leak syndrome [36]. If severe hypersensitivity occurs, therapy with Simulect should be permanently discontinued and no further dose should be administered [1]. Caution should be exercised when patients previously given Simulect are re-exposed to a subsequent course of therapy with this medicine.

There is accumulating evidence that a subgroup of patients is at increased risk of developing hypersensitivity reactions. These are patients in whom, following the initial administration of Simulect, the concomitant immunosuppression was discontinued prematurely due, for example, to abandoned transplantation or early loss of the graft. Acute hypersensitivity reactions were observed on re-administration of Simulect for a subsequent transplantation in some of these patients [20].

### Neoplasms and infections

Transplant patients receiving immunosuppressive regimens involving combinations with or without Simulect are at increased risk of developing lymphoproliferative disorders (LPDs) (such as lymphoma) and opportunistic infections (such as cytomegalovirus, CMV). In clinical trials, the incidence of opportunistic infections was similar in patients using immunosuppressive regimens with or without Simulect [4-8]. In a pooled analysis of two five-year extension studies, no differences were found in the incidence of malignancies and LPDs between immunosuppressive regimens with or without Simulect (see section 7 Adverse drug reactions) [17-19,36].

### Vaccination

No data are available on either the effects of live and inactive vaccination or the transmission of infection by live vaccines in patients receiving Simulect. Nevertheless, live vaccines are not recommended for immunosuppressed patients. Inactivated vaccines may be administered to immunosuppressed patients; however, response to the vaccine may depend on the degree of the immunosuppression.

## 7 Adverse drug reactions

### Summary of the safety profile

Simulect has been tested in four randomized, double-blind, placebo-controlled studies [4,5,7,8] in renal transplant recipients: in two studies patients were concomitantly treated with ciclosporin for microemulsion and corticosteroids (346 and 380 patients), in one study patients were concomitantly treated with ciclosporin for microemulsion, azathioprine and corticosteroids (340 patients) [4], in one study patients were concomitantly treated with ciclosporin for microemulsion, mycophenolate mofetil and corticosteroids (123 patients) [5].

Simulect has also been compared to a polyclonal anti-T-lymphocyte immunoglobulin preparation (ATG/ALG) in one active-controlled study in renal transplant recipients [6]; all patients were concomitantly treated with ciclosporin for microemulsion, mycophenolate mofetil and corticosteroids (135 patients). Safety data in pediatric patients have been obtained from one open-label pharmacokinetic and pharmacodynamic study in renal transplant recipients (41 patients) [3].

**Incidence of Adverse Events:** Simulect did not appear to add to the background of adverse events seen in organ transplantation patients as a consequence of their underlying disease and the concurrent administration of immunosuppressants and other medications. In the four placebo-controlled trials [4,5,7,8], the pattern of adverse events in 590 patients treated with the recommended dose of Simulect was indistinguishable from that in 595 patients treated with placebo. Simulect did not increase the incidence of serious adverse events observed when compared to placebo. The overall incidence of treatment-related adverse events among all patients in the individual studies was not significantly different between the Simulect (7.1% to 40%) and the placebo (7.6% to 39%) treatment groups. In the active-controlled study, fewer Simulect (11.4%) than ATG/ALG (41.5%) patients experienced treatment-related adverse events [6].

**Adult experience [4-8]:** The most commonly reported (>20%) events following dual or triple therapy in both treatment groups (Simulect vs. placebo or ATG/ALG) were constipation, urinary tract infection, pain, nausea, peripheral oedema, hypertension, anaemia, headache, hyperkalaemia, hypercholesterolaemia, postoperative wound complication, weight increase, increase in blood creatinine, hypophosphataemia, diarrhoea, upper respiratory tract infection.

**Pediatric experience [3]:** The most commonly reported (>20%) events following dual therapy in both (<35 kg vs. ≥35 kg weight) cohorts were urinary tract infection, hypertrichosis, rhinitis, pyrexia, hypertension, upper respiratory tract infection and viral infection, sepsis and constipation.

**Incidence of Malignant Neoplasms [4-8]:** The overall incidence of malignancies among all patients in the individual studies was similar between the Simulect and the comparator treatment groups. Overall, lymphoma/lymphoproliferative disease occurred in 0.1% (1/701) of patients in the Simulect group compared with 0.3% (2/595) of placebo and 0% of ATG/ALG patients.

Other malignancies were reported among 1.0% (7/701) of patients in the Simulect group compared with 1.2% (7/595) of placebo and 4.6% (3/65) of ATG/ALG patients.

No differences were found in the incidence of malignancies and LPDs between Simulect 7% (21/295) and placebo 7% (21/291) in a pooled analysis of two, five-year extension studies [17-19].

**Incidence of Infectious Episodes [4-8]:** The overall incidence and profile of infectious episodes among dual and triple therapy patients was similar between the Simulect and the placebo treatment groups (Simulect = 75.9%, placebo or ATG/ALG = 75.6%). The incidence of serious infections was similar in the Simulect and comparator groups (26.1% vs. 24.8%) [11]. The incidence of CMV-infections was similar in both groups (14.6% vs. 17.3%), following either dual or triple therapy regimen.

The incidence and causes of deaths following dual or triple therapy were similar in Simulect (2.9%) and placebo or ATG/ALG groups (2.6%), with the most common cause of deaths in both treatment groups being infections (Simulect = 1.3%, placebo or ATG/ALG = 1.4%) [4-8]. In a pooled analysis of two five-year extension studies the incidence and cause of death remained similar in both treatment groups (Simulect 15%, placebo 11%), the primary cause of death being cardiac-related disorders such as cardiac failure and myocardial infarction (Simulect 5%, placebo 4%) [17-19,36].

### **Listing of adverse drug reactions from post-marketing spontaneous reports [33,36]**

The following adverse drug reactions have been identified based on post-marketing spontaneous reports and are organized by system organ classes. Because these reactions are reported voluntary from a population of uncertain size, it is not always possible to reliably estimate their frequency.

#### **Immune system disorders**

Hypersensitivity/anaphylactoid reaction such as rash, urticaria, pruritus, sneezing, wheezing, bronchospasm, dyspnoea, pulmonary oedema, cardiac failure, hypotension, tachycardia, respiratory failure, capillary leak syndrome [1]. Cytokine release syndrome [20].

## **8 Interactions**

Because Simulect is an immunoglobulin, no metabolic drug-drug interactions are to be expected.

### **Concomitant medications routinely administered in organ transplantation**

In addition to ciclosporin for microemulsion, steroids, azathioprine and mycophenolate mofetil, other concomitant medications routinely administered in organ transplantation have been administered in clinical trials without any incremental adverse reactions. These concomitant medications include systemic antiviral, antibacterial and antimycotic medications, analgesics, antihypertensive medications such as beta-blocking agents or calcium channel blockers, and diuretics [4-8].

In the original phase 3 studies during the first 3 months post-transplantation, 14% of patients in the Simulect group and 27% of patients in the placebo group had an acute rejection episode

treated with antibody therapy (OKT 3 or ATG/ALG), with no increase in adverse events or infections in the Simulect group as compared to placebo [7,8].

Three clinical trials have investigated Simulect use in combination with a triple therapy regimen which included either azathioprine [4] or mycophenolate mofetil [5,6]. The total body clearance of Simulect was reduced by an average 22% when azathioprine was added to a regimen consisting of ciclosporin for microemulsion and corticosteroids. The total body clearance of Simulect was reduced by an average 51% when mycophenolate mofetil was added to a regimen consisting of ciclosporin for microemulsion and corticosteroids. The use of Simulect in a triple therapy regimen including azathioprine or mycophenolate mofetil did not increase adverse events or infections in the Simulect group as compared to placebo (see section 7 Adverse drug reactions").

### **Human antimurine antibody (HAMA)**

Human antimurine antibody (HAMA) responses were reported in a clinical trial of 172 patients treated with Simulect, without predictive value for clinical tolerability. The incidence was 2/138 in patients not exposed to muromonab-CD3 and 4/34 in patients who received muromonab-CD3 concomitantly [2]. The use of Simulect does not preclude subsequent treatment with murine antilymphocyte antibody preparations.

## **9 Pregnancy, lactation, females and males of reproductive potential**

### **9.1 Pregnancy**

#### **Risk Summary**

There is no adequate information for use in pregnant women. Simulect should not be given to pregnant women except in cases where the potential benefit for the mother outweighs the potential risk for the fetus.

#### **Animal Data**

No maternal toxicity, embryotoxicity, or teratogenicity was observed in cynomolgous monkeys 100 days *post coitum* following intravenous bolus injections of up to 5 mg/kg basiliximab administered twice weekly during the organogenesis period [24].

### **9.2 Lactation**

There is no animal or human data available concerning excretion of basiliximab into breast milk. However, since Simulect is an immunoglobulin G (IgG<sub>1K</sub>) antibody, it may cross the human placenta and may be excreted in human milk.

Women receiving Simulect should not breastfeed for 4 months following the last dose.

### **9.3 Females and males of reproductive potential**

#### **Contraception**

Females of reproductive potential should use adequate contraception to prevent pregnancy and continue its use for an additional 4 months after the last dose of Simulect [11-13].

### **Infertility**

No human data on the effect of basiliximab on fertility are available. Formal studies of the potential effect of Simulect on animal fertility have not been conducted.

## **10 Overdosage**

In clinical studies Simulect has been administered to humans in single doses of up to 60 mg and multiple doses of up to 150 mg over 24 days with no untoward acute effects.

## **11 Clinical pharmacology**

### **Pharmacotherapeutic group, ATC**

Pharmacotherapeutic group: Interleukin inhibitors; ATC code: L04A C02.

### **Mechanism of Action**

Simulect is a murine/human chimeric monoclonal antibody (IgG<sub>1κ</sub>) that is directed against the interleukin-2 receptor alpha-chain (CD25 antigen), which is expressed on the surface of T-lymphocytes in response to antigenic challenge. Simulect specifically binds with high affinity ( $K_D$ -value 0.1 nM) [10] to the CD25 antigen on activated T-lymphocytes expressing the high affinity interleukin-2 receptor and thereby prevents binding of interleukin-2, the signal for T-cell proliferation. Complete and consistent blocking of the interleukin-2 receptor is maintained as long as serum basiliximab levels exceed 0.2 micrograms/mL. As concentrations fall below this level, expression of the CD25 antigen returns to pretherapy values within 1 to 2 weeks. Simulect does not cause myelosuppression [7].

### **Pharmacokinetics (PK)**

Single-dose and multiple-dose pharmacokinetic studies have been conducted in patients undergoing kidney transplantation. Cumulative doses ranged from 15 mg up to 150 mg [28-30].

### **Absorption**

Peak serum concentration following intravenous infusion of 20 mg over 30 minutes is  $7.1 \pm 5.1$  mg/L [29]. There is a proportional increase in C<sub>max</sub> and AUC with dose up to the highest tested single dose of 60 mg [30].

### **Distribution**

The volume of distribution at steady state is  $8.6 \pm 4.1$  L [29,30]. The extent and degree of distribution to various body compartments have not been fully studied. *In vitro* studies using human tissues indicate that Simulect binds only to lymphocytes and macrophages/monocytes [27].

## Biotransformation/metabolism

Not applicable.

## Elimination

The terminal half-life is  $7.2 \pm 3.2$  days. Total body clearance is  $41 \pm 19$  mL/h [29,30].

## Characteristics in patients

No clinically relevant influence of body weight or gender on distribution volume or clearance has been observed in adult patients. Elimination half-life was not influenced by age (20 to 69 years), gender or race [32].

Disposition in adult liver transplant patients is characterized by a steady-state distribution volume of  $7.5 \pm 2.5$  L, half-life of  $4.1 \pm 2.1$  days and clearance of  $75 \pm 24$  mL/h. Contributing to clearance were drug loss via drained ascites fluid and post-operative bleeding. Offsetting the faster drug clearance was a lower receptor-saturating concentration threshold of 0.1 micrograms/mL in this population. Hence, the duration of IL-2Ralpha blockade at a given Simulect dose level is similar to that seen in adult renal transplant patients [31].

## Pediatric patients (below 18 years)

The pharmacokinetics of Simulect were assessed in 39 pediatric *de novo* renal transplantation patients [3]. In infants and children (age 1 to 11 years, n=25), the steady-state distribution volume was  $4.8 \pm 2.1$  L, half-life was  $9.5 \pm 4.5$  days and clearance was  $17 \pm 6$  mL/h. Distribution volume and clearance are reduced by about 50% compared to adult renal transplantation patients. Disposition parameters were not influenced to a clinically relevant extent by age (1 to 11 years), body weight (9–37 kg) or body surface area (0.44 to 1.20 m<sup>2</sup>) in this age group. In adolescents (age 12 to 16 years, n=14), the steady-state distribution volume was  $7.8 \pm 5.1$  L, half-life was  $9.1 \pm 3.9$  days and clearance was  $31 \pm 19$  mL/h. Disposition in adolescents was similar to that in adult renal transplantation patients. The relationship between serum concentration and receptor saturation was assessed in 13 patients and was similar to that characterized in adult renal transplantation patients [2].

## 12 Clinical studies

The efficacy of Simulect in prophylaxis of organ rejection in *de novo* renal transplantation has been demonstrated in double-blind placebo-controlled studies. Results from two pivotal 12-month multicenter studies [7,8] comparing Simulect with placebo show that Simulect, used concomitantly with ciclosporin for microemulsion and corticosteroids, significantly reduces the incidence of acute rejection episodes both within 6 (31% vs. 45%,  $p < 0.001$ ) and 12 (33% vs. 48%,  $p < 0.001$ ) months after transplantation. There was no significant difference between Simulect and placebo treated patients in graft survival after 6 and 12 months (at 12 months 32 graft losses on Simulect (9%) and 37 graft losses on placebo (10%)). The incidence of acute rejection episode was substantially lower in patients receiving Simulect and a triple drug immunosuppressive regimen.

Results from two multicenter double-blind studies comparing Simulect with placebo show that Simulect significantly reduces the incidence of acute rejection episodes within 6 months after transplantation when used concomitantly with ciclosporin for microemulsion, corticosteroids, and either azathioprine [4] (21% vs. 35%,  $p=0.005$  Fisher's exact) or mycophenolate mofetil [5] (15% vs. 27%,  $p=0.046$  K-M). Graft loss occurred in 6% of Simulect and 10% of placebo patients by 6 months. The adverse event profile remained comparable between treatment groups.

One 12-month active-controlled randomized open-label study [6] compared Simulect used concomitantly with early ciclosporin for microemulsion to a polyclonal anti-T-lymphocyte immunoglobulin preparation (ATG/ALG) with delayed ciclosporin for microemulsion. Both groups received corticosteroids and mycophenolate mofetil. Biopsy proven rejection occurred in 19% of Simulect and 20% of ATG/ALG treated patients within 12 months post-transplant.

In a pooled analysis of two five-year open-label extension studies (586 patients total) the combined graft and patient survival rates were not statistically different for the Simulect and placebo groups. Extension studies also showed that patients who experienced an acute rejection episode during the first year after transplantation experienced more graft losses and deaths over the five-year follow-up period than patients who had no rejection. These events were not influenced by Simulect [17-19].

Simulect was used concomitantly with ciclosporin for microemulsion and steroids in an uncontrolled study in pediatric *de novo* renal transplant recipients [3]. Acute rejection occurred in 14.6% of patients by 6 months post-transplantation, and in 24.3% by 12 months. Overall the adverse event profile was consistent with general clinical experience in the pediatric renal transplantation population and with the profile in the controlled adult transplantation studies.

Of 339 renal transplant patients treated with Simulect and tested for anti-idiotypic antibodies, 4 (1.2%) developed an anti-idiotypic antibody response [3,6,9]. In a clinical trial with 172 patients receiving Simulect, the incidence of human anti-murine antibody (HAMA) in renal transplantation patients treated with Simulect was 2/138 in patients not exposed to muromonab-CD3 and 4/34 in patients who received muromonab-CD3 concomitantly [2]. The available clinical data on the use of muromonab-CD3 in patients previously treated with Simulect suggest that subsequent use of muromonab-CD3 or other murine anti-lymphocytic antibody preparations is not precluded.

## 13 Non-clinical safety data

No local irritation potential was observed in a sensitive rabbit model intravenously injected with up to 4 mg/mL of basiliximab [22,23].

No toxicity was observed when rhesus monkeys received intravenous doses of either up to 5 mg/kg basiliximab twice weekly for 4 weeks followed by an 8-week withdrawal period or 24 mg/kg basiliximab weekly for 39 weeks followed by a 13-week withdrawal period [21,34,35]. The highest dose resulted in approximately 1,000 times the systemic exposure (AUC) observed in renal transplant patients given the recommended clinical dose together with concomitant immunosuppressive therapy.

No mutagenic potential was observed *in vitro* [25,26].

## 14 Pharmaceutical information

### Incompatibilities

No known incompatibilities.

### Special precautions for storage

Shipping and storage should be under refrigerated conditions (2 to 8°C).

### Instructions for use and handling

#### Simulect 10 mg

To prepare the infusion/injection solution, add 2.5 mL of sterile water for injection without any additive (for example Eur. Ph; USP or BP) aseptically to the vial containing the Simulect powder. Shake the vial gently to dissolve the powder. Use the reconstituted colourless, clear to opalescent solution as soon as possible, but it may be stored at 2 to 8°C for 24 hours or at room temperature for 4 hours. Discard the reconstituted solution if not used within 24 hours.

The reconstituted solution is isotonic and may be given as a bolus injection or diluted to a volume of 25 mL or greater with normal saline or dextrose 5% for infusion.

#### Simulect 20 mg

To prepare the infusion/injection solution, add 5 mL of sterile water for injection without any additive (for example Eur. Ph; USP or BP) aseptically to the vial containing the Simulect powder. Shake the vial gently to dissolve the powder. Use the reconstituted, colourless, clear to opalescent solution as soon as possible, but it may be stored at 2 to 8°C for 24 hours or at room temperature for 4 hours. Discard the reconstituted solution if not used within 24 hours.

The reconstituted solution is isotonic and may be given as a bolus injection or diluted to a volume of 50 mL or greater with normal saline or dextrose 5% for infusion.

Since no data are available on the compatibility of Simulect with other intravenous substances, Simulect should not be mixed with other medications/substances and should always be given through a separate infusion line.

Compatibility with the following infusion sets has been verified:

#### Infusion bag

- Baxter minibag NaCl 0.9%

#### Infusion sets

- Luer Lock™, H. Noolens
- Sterile vented i.v. set, Abbott
- Infusion set, Codan
- Infusomat™, Braun

- Infusionsgerät R 87 plus, Ohmeda
- Lifecare 5000™ Plumset Microdrip, Abbott
- Vented basic set, Baxter
- Flashball device, Baxter
- Vented primary administration set, Imed

Compatibility with other commercial devices has not been tested.

## 15 References

### References BPI amended 16 December 1999

1. Simulect (basiliximab). Overview of hypersensitivity/allergic reactions (basis for a proposal for a label change). Expert Report. Novartis Pharma AG. Basel, Switzerland. 17 Dec 99.
2. A multicenter, randomized, double-blind, placebo-controlled trial of SDZ CHI 621 for the prevention of acute cellular rejection in renal allograft recipients. Pharmacokinetic/Pharmacodynamic Analysis. Novartis Pharma AG. Basel, Switzerland. 26 Sep 97.

### Newly added references BPI amended 3 March 2000

		Volume	Page
3.	A multicenter, open-label, pharmacokinetic/pharmacodynamic, safety and tolerability study of Simulect in pediatric de novo renal transplant recipients. Study CHIB 152-E-00. Novartis Pharmaceutical Corp., East Hanover, NJ, USA. 08 Dec 99.	2*	001
4.	A multicenter, randomized, double-blind, placebo-controlled trial of Simulect for the prevention of acute rejection episodes in de novo kidney transplant recipients treated with Neoral, steroids and azathioprin. Study CHI INT 10. Novartis Pharma AG, Basel, Switzerland. 15 Feb 2000.	6*	001
5.	A multicenter, randomized, double-blind, placebo-controlled trial of Simulect in de novo kidney transplant recipients treated with Neoral, steroids and Cellcept for the prevention of acute rejection episodes. Study CHI INT 11. Novartis Pharma AG, Basel, Switzerland. 11 Feb 2000.	11*	001
6.	A multicenter, randomized, open-label trial of Simulect with early Neoral versus Atgam with delayed Neoral in de novo kidney transplant recipients. Study CHI US 01. Novartis Pharmaceutical Corp., East Hanover, NJ, USA. 18 Jan 2000.	14*	001
7.	A multicenter, randomized, double-blind, placebo controlled trial of Simulect for the prevention of acute cellular rejection in renal allograft recipients. Integrated Clinical and Statistical Study Report CHIB 201-E-00. Novartis Pharmaceuticals Corporation. East Hanover, New Jersey, USA. 01 Oct 97.	2 <sup>Δ</sup>	378
8.	A multicenter, randomized, double-blind, placebo controlled trial of SDZ CHI 621 for the prevention of acute cellular rejection in renal allograft recipients. Integrated Clinical and Statistical Study Report CHIB 352-E-00. Novartis Pharmaceuticals Corporation. East Hanover, New Jersey, USA. 30 Sep 97.	10 <sup>Δ</sup>	1
9.	Integrated clinical and statistical study report. Study (protocol) no: CHIB 105-E-00. Sandoz Pharma Ltd. Basel, Switzerland. 29 Nov 96.	1 <sup>Δ</sup>	344
10.	SDZ CHI 621 Drug substance solution. Determination of biological activity. Control procedure 408.01-E-001. Novartis Pharma AG. Basel, Switzerland. 10 Jul 97.	2 <sup>Δ</sup>	143

<sup>Δ</sup> = in the IRD from 1997.

\* = in the IRD from March 2000.

### Newly added references BPI amended 22 August 2001

11. Simulect (basiliximab) SDZ CHI 621. Expert report on the clinical documentation. Novartis Pharma AG. Basel, Switzerland. 14 Feb 00.
12. A multicenter, randomized, double-blind, placebo-controlled trial of Simulect for the prevention of acute rejection episodes in *de novo* kidney transplant recipients treated with Neoral, steroids and azathiopurin. Appendix 8.2: Pharmacokinetic evaluation. Study CHI INT 10. Novartis Pharma AG, Basel, Switzerland. 28 Dec 99.
13. A multicenter, randomized, open-label trial of a regimen of Simulect with early Neoral versus ATGAM with delayed Neoral in *de novo* kidney transplant recipients. Appendix 8.2: Pharmacokinetic evaluation. Study CHI 621 US-01. Novartis Pharma AG, Basel, Switzerland. 14 Jan 00.
14. Simulect (CHI 621). 20 mg/vial lyophilisate for injection. RSR5000A. Registration stability report. Novartis Pharma AG. Basel, Switzerland. 14 Feb 00.

### **Newly added references BPI amended 08 May 2002**

15. Simulect 10 mg powder for solution for injection, KN 3734506.00.005. Expert Report on the chemical, pharmaceutical and biological documentation. Novartis Pharma AG. Basel, Switzerland. 13 Jun 02.
16. Simulect 10 mg powder for solution for injection. RSR5029 Summary-1A. Registration stability report. Summary and conclusions. Novartis Pharma AG. Basel, Switzerland. 06 Jun 02.

### **Newly added references BPI amended 23 May 2003**

17. Multicenter, randomized, double-blind, placebo controlled trials of Simulect for the prevention of acute cellular rejection in renal allograft recipients: five year survival following open-label study extensions. Study No: CHIB 201-E-01 and CHIB 352-E-01. Novartis Pharma AG. Basel, Switzerland. 25 Jan 02.
18. Multicenter, randomized, double-blind, placebo controlled trials of Simulect for the prevention of acute cellular rejection in renal allograft recipients: five year survival following open-label study extensions. Study No: CHIB 201-E-01 and CHIB 352-E-01 (amendment 1). Novartis Pharma AG. Basel, Switzerland. 14 Feb 02.
19. Expert Statement. Simulect (basiliximab). CHIB201-E-01 and CHIB352-E-01. Results from 5-year study extensions. Novartis Pharma AG. Basel, Switzerland. 04 Apr 02.

### **Newly added references BPI amended 18 March 2005**

20. Expert Statement Comprehensive Medical Safety Evaluation. Simulect® (basiliximab). Change in the Company Core Data Sheet. Cytokine release syndrome; Hypersensitivity reactions at re-exposure. Novartis AG. Basel, Switzerland. 22 Feb 05.
21. SDZ CHI 621: 4- week intravenous toxicity study in Rhesus monkey with an 8-week treatment free period. Study 1463-034. Novartis Pharma AG. Basel, Switzerland. Covance Laboratories. Münster, Germany. 30 Sep 97.
22. SDZ CHI 621: A local intravenous tolerance study in rabbits. Study 66LT-RB. Sandoz. Basel, Switzerland. 12 Jul 91.
23. SDZ CHI 621: Local tolerance study following single intravenous infusion in rabbit. Study 252/128-1032. Sandoz. Basel, Switzerland. Hazleton. 10 Mar 95.

24. SDZ CHI 621: Intravenous embryo-fetal development study in the cynomolgus monkey. Study 1325-252-196. Novartis Pharma AG. Basel, Switzerland. Covance Laboratories. Münster, Germany. 12 Sep 97.
25. SDZ CHI 621: Mutagenicity test using Salmonella typhimurium. Study MutBakt 69/96. Novartis Pharma AG. Basel, Switzerland. 05 Jun 97.
26. SDZ CHI 621: Chromosomal aberration test with V79 Chinese hamster cells. Study Z64. Novartis Pharma AG. Basel, Switzerland. 20 May 97.
27. SDZ CHI 621: Reactivity with human tissues. Sandoz Pharma AG. Basel, Switzerland. P.L. Amlot, Royal Free Hospital School of Medicines. London, UK. 12 Aug 91.
28. Safety and tolerability of SDZ CHI 621 given as prophylaxis for acute rejection in kidney transplant patients: Pharmacokinetic/Pharmacodynamic Analysis. Supplement No 1 to Clinical Study Report CHIB 101-E-00. Sandoz Pharma Ltd. Basel, Switzerland. 16 Sep 96.
29. Kovarik JM, Legay F. Safety and tolerability of SDZ CHI 621 given as prophylaxis for acute rejection in kidney transplant patients: Pharmacokinetic/Pharmacodynamic Analysis. Supplement No 1 to Clinical Study Report CHIB 105-E-00. Novartis AG. Basel, Switzerland. 02 Mar 97.
30. Safety, tolerability and pharmacokinetics of three doses of SDZ CHI 621 given as prophylaxis for acute rejection in kidney transplant recipients: Pharmacokinetic/Pharmacodynamic Analysis. Supplement No 1 to Clinical Study Report CHIB 106-E-00. Novartis Pharma AG. Basel, Switzerland. 14 Mar 97.
31. An open-label study of the pharmacokinetics and pharmacodynamics, safety and tolerability of SDZ CHI 621 in de novo liver transplant recipients: Pharmacokinetic/Pharmacodynamic Analysis. Supplement No 1 to Clinical Study Report CHIC 101-E-00. Novartis Pharma AG. Basel, Switzerland. 23 Sep 97.
32. Summary of the human pharmacokinetics and bioavailability of basiliximab. Novartis Pharma AG. Basel, Switzerland. 10 Nov 97.

### **Newly added references BPI amendment 28 September 2005**

33. A. Vilimovskij. Simulect® (basiliximab). Clinical Overview: update of section 4.8 Undesirable effects of the BPI. Novartis. Basel, Schweiz. 29 Aug 05.
34. A. de Brugerolle, P. Marbach. Simulect® (basiliximab). Non-clinical overview. Update on toxicological data. Novartis. Basel, Schweiz. 02 Sep 05.
35. A. de Brugerolle. Simulect® (basiliximab). Toxicology written summary. Update on toxicological data. Novartis. Basel, Schweiz. 02 Sep 05.

### **Newly added references - CDS update v1.0 - 12-Apr-2011**

- 36 Simulect (basiliximab. 2.5 Clinical Overview: Rationale for changes to Core Data Sheet (CDS)/Product Information – Update of the safety sections. Novartis. 16-Feb-2011

### **No newly added reference - CDS update v2.0 - 13-Jan-2014**

No added reference supporting this update (format changes only)

### **No newly added reference - CDS update v3.0 – 12-Dec-2017**

No added reference supporting this update (format changes only)

## No newly added reference - CDS update v3.1 – 29-Sep-2023

No added reference supporting this amendment (added new presentation without water for injection (WFI) ampoule)

### 16 CDS history table

Version	Effective date	GLC/PSB approval date	SLC Tracking No.	Section keyword	Refs.	Author(s) GLM/GPRD/GPRM
1.0	12-Apr-2011	16-Feb-2011	2011-PSB/GLC-0370-s	Update	36	Cebe St
2.0	13-Jan-2014	10-Dec-2013	N/A	Update	-	Duverger B
3.0	N/A	12-Dec-2017	N/A	Full review/update with only editorial changes; not dispatched	-	Armstrong T
3.1	29-Sep-2023	15-Sep-2023	N/A	Amendment to support a new presentation without water for injection (WFI) ampoule	-	K. Priyanka

### 17. Marketing Authorization Number

- Simulect 20mg powder and solvent for solution for infusion or injection - NAFDAC Reg. No: A6-0405